A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).
Disease, Hodgkin
DRUG: brentuximab vedotin|DRUG: placebo
Progression-free Survival by Independent Review, Time from date of randomization to the first documentation of disease progression by independent review or to death due to any cause, whichever comes first, Up to approximately 4 years
Overall Survival, Time from date of randomization to date of death due to any cause, Up to approximately 10 years|Incidence of Adverse Events or Laboratory Abnormalities, Up to 12 months|Incidence of Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin, Up to 12 months
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).